Zoetis is a global leader in animal health, dedicated to providing innovative products and solutions that enhance the health and well-being of animals
The company develops a broad range of medicines, vaccines, and diagnostic tools for both livestock and companion animals, supporting veterinarians and producers in improving animal health through science-based products. With a commitment to advancing veterinary medicine and sustainability, Zoetis works to ensure safe and sustainable food supply chains while enhancing the quality of life for pets and livestock around the world.
Zoetis Inc. (NYSEZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 13, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2024 financial results and respond to questions from financial analysts during the call.
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
The Board of Directors of Zoetis Inc. (NYSEZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% from the quarterly dividend rate paid in 2024. The dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 21, 2025.
Zoetis Inc. (NYSEZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 11:30 a.m. ET.
Zoetis Inc. (NYSEZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world’s leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company’s long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities.
Zoetis Inc. (NYSEZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT.
Zoetis Inc's Q3 2024 results show a 16% EPS increase and an 11% revenue boost. The company raises its 2024 guidance, highlighting strong global growth in key segments.
Zoetis Inc. (NYSEZTS) today reported its financial results for the third quarter of 2024 and raised its full year 2024 guidance for revenue and adjusted EPS.
